ERYTHROPOIETIN IN CLINICAL APPLICATIONS: AN INTERNATIONAL PERSPECTIVE

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

ERYTHROPOIETIN IN CLINICAL APPLICATIONS: AN INTERNATIONAL PERSPECTIVE

Erythropoietin in Clinical Applications: An International Perspective. Garnick MB, ed. New York, Marcel Dekker, 334 p., 1990.. Unique Identifier : AIDSLINE ICDB/91676843
Anonymous; No affiliation given

Abstract: Advances in recombinant DNA technology leading to the development, manufacture, and establishment of the clinical efficacy and safety of naturally occurring human proteins, are having a profound impact on the day-to-day practice of medicine. The availability of recombinant human erythropoietin, a blood growth factor, marks yet another new horizon. The use of erythropoietin has substantially and beneficially changed the lives of thousands of patients (pts) with anemia secondary to chronic renal failure. The potential for erythropoietin to result in meaningful therapeutic advances in an even broader range of diseases is realistic. Expectations are that pts worldwide will benefit from the therapeutic administration of erythropoietin for diverse indications, including cancer chemotherapy and AIDS, as well as from its prophylactic use in autologous blood storage. The clinical use of erythropoietin is reviewed, including its history, molecular biology, biochemistry, and biology; the pathogenesis of anemia secondary to chronic renal failure; treatment of pts with renal anemia with recombinant human erythropoietin (European experience); erythropoietin treatment of pts with end-stage renal disease (North American and Japanese experience); the use of erythropoietin in predialysis pts; quality of life issues with erythropoietin; potential use of erythropoietin in the pediatric population; erythropoietin in the surgical setting; and erythropoietin therapy for the anemia associated with AIDS, AIDS therapy, and cancer.

Keywords: Acquired Immunodeficiency Syndrome/THERAPY Adult Anemia/THERAPY Child Erythropoietin/*THERAPEUTIC USE Hemodialysis Human Kidney Failure, Chronic/THERAPY Neoplasms/THERAPY Recombinant Proteins/THERAPEUTIC USE MONOGRAPH

911130
M91B0824

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .